From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

RECEIVED PCT JAMES F. HALEY C/O FISH & NEAVE NOTIFICATION OF TRANSMITTAL OF 1251 AVENUE OF THE AMERICAS MAR 2 5 2004 NEW YORK, NY 10020 INTERNATIONAL PRELIMINARY **EXAMINATION REPORT** FISH & NEAVE - PATENT DEPT. REFERRED TO (PCT Rule 71.1) STED BY Date of Mailing 22 MAR 2004 (day/month/year) Applicant's or agent's file-reference OU HAVE SEEN IT IMPORTANT NOTIFICATION GFI/102 PCT International filing date (day/month/year) Priority date (day/month/year) International application No. PCT/US02/41510 24 December 2002 (24.12.2002) 27 December 2001 (27.12.2001) Applicant GLYCOFI, INC.

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Deborah Crouch, Ph.D.

Telephone No. 703-308-0196

F.D.R. for

Form PCT/IPEA/416 (July 1992)

POR O PCTEPING SAMON ZUU4

TENT COOPERATION TREATY

PCT

REC'D 24 MAR 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPOR (PCT Article 36 and Rule 70)

WIPO PCT

GFI/102 PCT	FOR FURTHER ACTIO	FION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)					
International application No.	International filing date (day)	nonth/year)	Priority date (day/month/year)				
PCT/US02/41510	24 December 2002 (24.12.20		27 December 2001 (27.12.2001)				
International Patent Classification (IPC)	or national classification and IF	С					
IPC(7): A01K 67/027; C12N 9/10, 1/04, 1/16, 1/18 and US Cl.: 800/13-18; 435/193, 252.3, 254.11, 254.51, 254.21, 254.23, 254.3, 254.4, 254.6, 254.7, 325, 463							
Applicant							
GLYCOFI, INC.							
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.							
2. This REPORT consists of a total of 2 sheets, including this cover sheet.							
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
These annexes consist of a total of \int sheets.							
3. This report contains indica	ations relating to the following	ng items:					
I Basis of the report							
II Priority	II Priority						
III Non-establishm	III Non-establishment of report with regard to novelty, inventive step and industrial applicability						
IV Lack of unity of	f invention						
	tations and explanations sup						
VI Certain docume	nts cited						
VII Certain defects	VII Certain defects in the international application						
VIII Certain observations on the international application							
Date of submission of the demand		Date of completion of this report					
03 July 2003 (03.07.2003)		27 February 2004 (27.02.2004)					
Name and mailing address of the IPEA/US		thorized officer	V0 0 1				
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents	D	eborah Crouch, Ph	a.D. F.D. R. 407				
P.O. Box 1450 - Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		lephone No. 703-3	08-0196				

International at ion No.	_
PCT/US02/41510	

I.	Basis of the report	
1.	. With regard to the elements of the international application:*	
	the international application as originally filed.	
	the description:	
	pages 1-71 as originally filed pages NONE , filed with the demand	
	pages NONE , filed with the letter of	•
	the claims:	
	pages 72-79 , as originally filed	ř
	pages NONE , as amended (together with any statement) under Article 19	
	pages NONE, filed with the demand pages NONE, filed with the letter of	
	the drawings:	-
	pages 1-46, as originally filed	
	pages NONE , filed with the demand	
	pages NONE, filed with the letter of	
	the sequence listing part of the description: pages NONE, as originally filed	
	pages NONE, as originally lifed pages NONE, filed with the demand	
	pages NONE , filed with the letter of	
2;	. With regard to the language, all the elements marked above were available or furnished to this A	
	language in which the international application was filed, unless otherwise indicated under this iter. These elements were available or furnished to this Authority in the following language which	
	the language of a translation furnished for the purposes of international search (under Rule23	.1(b)).
	the language of publication of the international application (under Rule 48.3(b)).	•
	the language of the translation furnished for the purposes of international preliminary examination 55.2 and/or 55.3).	ation(under Rules
3.	. With regard to any nucleotide and/or amino acid sequence disclosed in the international application international preliminary examination was carried out on the basis of the sequence listing:	ion, the
	contained in the international application in printed form.	
	filed together with the international application in computer readable form.	
	furnished subsequently to this Authority in written form.	
	furnished subsequently to this Authority in computer readable form.	
	The statement that the subsequently furnished written sequence listing does not go beyond the international application as filed has been furnished.	disclosure in the
	The statement that the information recorded in computer readable form is identical to the wri has been furnished.	tten sequence listing
4.	The amendments have resulted in the cancellation of:	
	the description, pages NONE	
	the claims, Nos. NONE	•
	the drawings, sheets/fig NONE	
5.	This report has been established as if (some of) the amendments had not been made, since they have be beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	en considered to go
this	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article is report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules * Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this repo	70.16 and 70.17).

Form PCT/IPEA/409 (Box I) (July 1998)

International approximation No. PCT/US02/415	

,- -									
V. Reasoned statement under Rule 66. citations and explanations supporting	2(a)(ii) with regarding such statement	d to novelty, in	ventive step or indus	strial applicability;					
1. STATEMENT									
Novelty (N)	Claims	1-60		YES					
• , ,	Claims	NONE		NO					
				•					
Inventive Step (IS)	Claims			YBS					
	Claims	NONE		NO					
	Gt :			YES					
Industrial Applicability (IA)	Claims			NO NO					
	Claims	NONE		NO					
a nucleic acid molecule having at least 45 consecutive nucleotide residues of figure 6, vectors and cells comprising the residues, methods to enhance the degree of glucosylation of lipid-marked oligosaccharides, methods for producing in non-mammalian cell an immunoglobulin peptide having an N-glycan comprising a bisecting GlcNAC, a non mammalian host cell producing the immunoglobulin, a method for producing human-like glycoprotein in a nonhuman eukaryotic host cell or a method for producing a human-like glycoprotein having an N-glycan comprising at least two GlcNAcs attached to a trimannose core. Claims 1-60 meet the criteria set out in PCT Article 33(4), and thus meet industrial applicability because the subject matter claimed can be made or used in industry.									
		٠.							
			•						

Form PCT/IPEA/409 (Box V) (July 1998)